FY24 facilities task order g B376 renovate rooms 204-207
Ended Awarded Last action
- Contract number
- 75N91024F00025
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,079,915
Award facts
- Opportunity
-
- NCIOSFM240082 Solicitation number
- Contract value 100% obligated
- $1,079,915.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$100,401 | |
| Terminate for Convenience | $0 | |
| Original award | $1,180,316 |
About this award
The National Cancer Institute awarded a $1.08M delivery order to Leidos Biomedical Research Inc. on July 8, 2024, for FY24 facilities renovation work targeting rooms 204-207 at the Frederick, Maryland location. This cost-plus-fixed-fee delivery order is part of the agency's capital improvement efforts and carries an ultimate completion date of April 10, 2026. The contract was awarded without a set-aside designation, reflecting the competitive capabilities of Leidos Biomedical Research Inc., which operates as a Federally Funded Research and Development Center (FFRDC) contractor providing comprehensive biomedical research and facilities support services to the National Cancer Institute and broader federal research community.
Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc., a prominent defense and technology contractor headquartered in Reston, Virginia. As an FFRDC operator for NCI, the company delivers critical research infrastructure, facility management, and operational support services. The company's portfolio includes work on cancer research, clinical trials, gene therapy development, and laboratory testing capabilities. This facilities renovation task order supports NCI's ongoing infrastructure modernization efforts at the Frederick National Laboratory for Cancer Research, enabling continued advancement of the agency's medical research mission.
Quick answers
Who was awarded contract 75N91024F00025?
75N91024F00025 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on July 8, 2024.
How much is contract 75N91024F00025 worth?
The government has obligated $1,079,915 on 75N91024F00025.
Is contract 75N91024F00025 an order under another contract?
Yes. 75N91024F00025 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00025 competed?
The extent of competition for 75N91024F00025 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award